Sakditad “Tew” Saowapa, MD
@SakditadMD
PGY-4 Heme/Onc fellow @uiowacancer | IM @TTUHSC 🇺🇸 🇹🇭| 2024 @ASCO Annual Meeting Merit Award Recipient | $TSLA investor 🚗⚡️ | Thoracic/H&N/GI onc
💚 I’m incredibly honored and humbled to share that I scored in the 100th percentile on the Internal Medicine In-Training Exam (ITE), as reported by the American College of Physicians (ACP)—placing me among the top PGY-3 residents nationwide. 🇺🇸 🙏 My program recognized this…



🏅 Honored to receive a 2025 Conquer Cancer Merit Award from @ConquerCancerFd @ASCO for our abstract on lung cancer disparities—selected for poster presentation at #ASCOQLTY25! 📌 Survival Disparities in NSCLC: Disaggregating Asians from NHPI in Hawaiʻi 🙏 Thank you to the…
This is huge! @Sai_Wannaphut Congratulations! For the great work!! 🤩🥳🙌🏽
🏅 Honored to receive a 2025 Conquer Cancer Merit Award from @ConquerCancerFd @ASCO for our abstract on lung cancer disparities—selected for poster presentation at #ASCOQLTY25! 📌 Survival Disparities in NSCLC: Disaggregating Asians from NHPI in Hawaiʻi 🙏 Thank you to the…
🙏 Help Needed 🙏 Leonardo Santiago Torres, a 23-year-old from Lubbock, is in kidney failure and desperately needs a donor. His blood type is O+, but O- and O+ donors can help. 📍 Read his story & how you can help: everythinglubbock.com/news/local-new… 📞 Donor info: Call UMC Transplant at…
Terrific presentation on utilization of social media, by the master @StephenVLiu! Personally, have learned so much and formed multiple meaningful connections through social media! @IASLC Academy @ChristianRolfo @RManochakian @LuisRaezMD @IvyLorena_Md @acmoorephd
To help stop cancer misinformation on social media, health care providers can participation in social networks to see the types of content to which their patients are exposed, disseminate evidence‐based information, and correct misinformation. acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca… @LoebStacy
Treatment Algorithm: This is the algorithm we have used during our discussion w/ @Anand_88_Patel for AML! #OncTwitter #MedTwitter #HemeTwitter @OncUpdates
Treatment Algorithm series: Acute Myeloid Leukemia (AML) w/ @Anand_88_Patel ✅ Importance of molecular testing ✅ Rx for fit/unfit pts ✅ R/R disease Full discussion: - Oncbrothers.com/algo-AML-2025 - Also on the “Oncology Brothers” podcast #HemeTwitter #OncTwitter @OncUpdates
❗️MUTYH mutant #pancreatic #NET (germline/somatic) ✅3% ✅50% second hit genetic event ✅2/3 G1/2 evolved to G3 ✅3/7 tumors molecularly profiled after alkylating drugs and/or PRRT had high TMB ✅ aggressive , high-grade disease when metastatic @TAMedOncol @gitorrezan
‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! @OncoAlert
🔥🚨Hot Off the Press #BigNews Press Release by @AstraZeneca ⭐️#FLAURA2 trial of #Osimertinib + #Chemotherapy vs #Osimertinib in 1st line Tx for patients with #EGFR+ advanced #LungCancer (#NSCLC) shows: ✅Statistically Significant & Clinically Meaningful Improvement in…
🧬 Adjuvant chemo in pT4N0 colon cancer: real-world evidence 🔗 esmoopen.com/article/S2059-… 📈 6-month oxaliplatin-based chemo improves OS & RFS ⏳ 3-month also helpful, but less so 🧪 MMR status not prognostic
Dr. @triparnasen reviews updates on biomarkers and the classification of SCLC. An important point noted here: SCLC subtypes are heterogenous AND plastic, further enhanced by treatment! #BTGLung2025
Improving #OncologyCare! Check out our latest standards update on the Oncology Medical Home. Read the full article: brnw.ch/21wUjjy
Press release, press release! OS-imertinib and chemo are making the oncology Jumbotron today- and with a very hot play on OS they have nothing to hide! With OS being the 🐘in the room and both MARIPOSA and FLAURA2 reaching this key endpoint- the pendulum has clearly swung in…
EBV related cancer: 1. PTLD 2. NK/T cell lymphoma 3. Some Hodgkin 4. African Burkitt’s 5. 10% Gastric Ca 6. Rare sarcomas 7. EBV+ DLBCL NOS 8. Nasopharyngeal CA Please add if I missed some.
✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,…
Wishing Supriya all the best as she enters this Hematology-Oncology fellowship application cycle! Her strong passion for GI Oncology, dedication to clinical trials, and focus on healthcare disparities make her an outstanding candidate. Any program would be lucky to have her on…
It feels truly surreal to be entering this hematology-oncology fellowship application cycle, pursuing my passion for GIOncology. My interests focus on GI cancers, early-onset malignancies, and healthcare disparities, with a special focus on clinical trials. Grateful to all my…
New global statement in Journal of Thoracic Oncology highlights major gaps in access to Molecular Tumour Boards (MTBs) - key to personalised #lungcancer care. LuCE supports @IASLC’s call for better infrastructure, wider testing & virtual MTBs. 🔗 jto.org/article/S1556-… #LCSM
Eating nutritious foods can help cancer survivors manage their energy levels, feel better, and stay stronger. 🥗🍉🍇 Our infographic shares general tips for eating well during treatment. Access the full @AmericanCancer recommendations: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… @OncoAlert
🚀 Officially submitted my ERAS application for the 2026 Hematology/Oncology Fellowship Match! Grateful for the mentors, patients, and friends who’ve shaped this journey. Looking forward to the next chapter in cancer care, equity, and innovation. 🙏🏽✨ 📋 AAMC ID: 14490577…